STAT3 and breast cancer: Additional novel STAT3 inhibitors that have been investigated preclinically for the treatment of breast cancer include: LLY17, 6Br-6a, napabucasin, and coumarin-benzo[b]thiophene 1, 1-dioxide conjugates (Table 1) (179, 181, 187, 188).